OCTAPHARMA AG

History

Year	Detail
1983	Wolfgang Marguerite established Octapharma to treat people with hemophilia and allow access to better products.
1985	The company introduced Octavi, a virally inactivated FVIII concentrate medicine developed using the S/D method available to hemophilia patients.
1999	Octapharma AG acquired Aventis's production site based in Lingolsheim, France, to maximize the production capacity at the site in Mexico.
2002	Octapharma AG acquired Biovitrum's third manufacturing site to increase its products portfolio to increase product portfolio in Stockholm, Sweden.
2006	The company has acquired five plasma donation centers from Deutsche Gesellschaft für Human plasma.
2007	Octapharma Plasma Inc. was established to operate its plasma donation centers in the U.S.
2012	Octapharma AG opened the Institute for Recombinant Protein Research & Development to further invest in advanced therapies in Heidelberg, Germany.
2016	Panzyga received regulatory approvals in Canada and the EU for primary immunodeficiency syndromes and immune thrombocytopenia.
2023	European authorities have approved the lyophilized presentation of Octapharma's pooled S/D treated human plasma, octaplasLG, used for transfusion in a pre-hospital setting.